Skip to content

PRIMROSE LABORATORIES

Active
Public limited companyfounded 2006active for 20 yearsKwaplasstraat 71, 8820 Torhout, BelgiumKBO/BCE: BE 0879.952.227
Summary

The computed 12-month bankruptcy probability of PRIMROSE LABORATORIES is 2.0% (moderate). The 2024 annual accounts show negative equity (-€1.4m) and a net result of €23,859. Equity is shrinking by about 4% per year across the filed financial years. Its solvency ranks better than 5% of 2,145 sector peers (NACE 86, financial year 2024). The company has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals.

Overview

Activity
Medical imaging and medical laboratories
NACE 86910Manufacture of chemicals and chemical products NACE 20590
9th largest company by total assets in Torhout, Health and social work sector1 site
Size
€1.9mtotal assets 2024
Staff
5.2 FTE
Equity
-€1.4m
Profit
€23,859
Turnover not published (abbreviated format)
Financial health
52 Fair Checked score 2024
Bankruptcy probabilitywithin 12 months
2.0%
Structure
Largest shareholder
SEA-HORSE · 33%
Holdings
1
Accounts 73 days overdue0 of 9 deeds read
Why 52raises riskLiquidity: current ratio 0.43, cash €112, halvedFigures for financial year 2024 (filed 11-08-2025)Negative equity -€1.4mlowers riskSector: Human health activities (NACE 86)Show the evidence

Checked score

Score 2024
52 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 12% of its sector peers (NACE 86, micro)
Financial strength · tick = 2023
Weak
Solvency 0=
equity -74.8% of total assets
Liquidity 3-2
short-term debt 84.7% · cash 0.0%
Profitability 35+7
return on assets 1.3%
Bankruptcy probability, 12 months
2.0% Moderate
0%0.5%1.5%4%10%≥ 25%

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,042 companies, NACE 86, micro)
Last 24 months 11-2024: 1.0% 12-2024: 1.0%● unchanged vs 11-2024 01-2025: 1.0%● unchanged vs 12-2024 02-2025: 1.1%▲ +0.1 percentage points vs 01-2025 03-2025: 1.1%● unchanged vs 02-2025 04-2025: 1.1%● unchanged vs 03-2025 05-2025: 1.1%● unchanged vs 04-2025 06-2025: 1.1%● unchanged vs 05-2025 07-2025: 1.3%▲ +0.2 percentage points vs 06-2025 08-2025: 1.7%▲ +0.4 percentage points vs 07-2025 09-2025: 0.9%▼ -0.8 percentage points vs 08-2025lowest value 10-2025: 0.9%● unchanged vs 09-2025lowest value 11-2025: 0.9%● unchanged vs 10-2025lowest value 12-2025: 0.9%● unchanged vs 11-2025lowest value 01-2026: 0.9%● unchanged vs 12-2025lowest value 02-2026: 0.9%● unchanged vs 01-2026 03-2026: 1.0%▲ +0.1 percentage points vs 02-2026 04-2026: 1.0%● unchanged vs 03-2026 05-2026: 1.0%● unchanged vs 04-2026 06-2026: 1.0%● unchanged vs 05-2026 07-2026: 1.1%▲ +0.1 percentage points vs 06-2026 08-2026: 1.5%▲ +0.4 percentage points vs 07-2026 09-2026: 1.8%▲ +0.3 percentage points vs 08-2026 10-2026: 2.0%▲ +0.2 percentage points vs 09-2026highest value
No credit on open account
Liquidity insufficient (current ratio 0.43, compared with 0.42 in 2023, below 1; short-term debt: 84.7% and cash: 0% of total assets), and equity is negative.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro): better than 1% on solvency, 1% on liquidity, 6% on profitability and 41% on growth.

The bankruptcy probability was computed on 12-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Seven signals.
lowers riskraises riskneutral
raises risk · Liquidity: current ratio 0.43, cash €112, halved
NBB · annual accounts
lowers risk · Sector: Human health activities (NACE 86)
KBO
raises risk · Figures for financial year 2024 (filed 11-08-2025)
NBB · annual accounts
raises risk · Negative equity -€1.4m
NBB · annual accounts
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 5% of 2145 sector peers (2024).
NBB · sector comparison
Position among 2145 sector peers
Solvency
better than 5%
← weakest strongest →
raises risk · Annual accounts not filed
The financial year that closed on 31-12-2025 was due at the National Bank by 31-07-2026. Nothing is on record, 73 days later.
NBB · 10 filings
Position against the passed deadline
31-12-2025 year end31-07-2026 deadline12-10-2026 today
neutral · A punctual record breaks
This company filed 5 consecutive financial years on time. The year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 08-08-2025, 8 days late. Weigh it accordingly: of the companies that move to filing 1 to 90 days late, 1.41% are now bankrupt, dissolved or in another special legal status, below the 1.66% of all filers. It is a change in behaviour, not evidence of elevated risk.
NBB · 10 filings
Deviation from the deadline
2025
not filed
2024
8 days late
2023
12 days early
2022
11 days early
2021
11 days early
2020
19 days early
2019
18 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 6 accounts on average 11 days before the deadline; the sector median (NACE 86) for financial year 2024 is 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (1)
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2024 · abbreviated…
  2. Back to profitnet €23,859
  3. Annual accounts filedfinancial year 2023 · abbreviated…

Key points

  • Risk: Negative equityfinancial year 2024: debts exceed assets -€1.4m View
  • Caution: Among the weakest 5% on solvencysector median 63.6% · 2,145 companies -74.8% View
  • Caution: Accounts not fileddeadline was 31-07-2026 73 days late View

By topic

Financials

Financial year
2024
Total assets
€1.9m
Profit
€23,859
Solvency
-74.8%
Total assets▲ 0.9%
Net result
20182024
Go to Financials

Timeline

Events
22
Since
2007
  1. 20-07-2023Annual accounts filed
  2. 31-12-2022Back to profit
  3. 20-07-2022Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Medical imaging and medical laboratoriesNACE 86910
Founded
14-03-2006
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.